Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Res ; 78(20): 5833-5847, 2018 10 15.
Article in English | MEDLINE | ID: mdl-30154152

ABSTRACT

Mutations in the tumor suppressor p53 are the most frequent alterations in human cancer. These mutations include p53-inactivating mutations as well as oncogenic gain-of-function (GOF) mutations that endow p53 with capabilities to promote tumor progression. A primary challenge in cancer therapy is targeting stemness features and cancer stem cells (CSC) that account for tumor initiation, metastasis, and cancer relapse. Here we show that in vitro cultivation of tumors derived from mutant p53 murine bone marrow mesenchymal stem cells (MSC) gives rise to aggressive tumor lines (TL). These MSC-TLs exhibited CSC features as displayed by their augmented oncogenicity and high expression of CSC markers. Comparative analyses between MSC-TL with their parental mutant p53 MSC allowed for identification of the molecular events underlying their tumorigenic properties, including an embryonic stem cell (ESC) gene signature specifically expressed in MSC-TLs. Knockout of mutant p53 led to a reduction in tumor development and tumorigenic cell frequency, which was accompanied by reduced expression of CSC markers and the ESC MSC-TL signature. In human cancer, MSC-TL ESC signature-derived genes correlated with poor patient survival and were highly expressed in human tumors harboring p53 hotspot mutations. These data indicate that the ESC gene signature-derived genes may serve as new stemness-based prognostic biomarkers as well as novel cancer therapeutic targets.Significance: Mesenchymal cancer stem cell-like cell lines express a mutant p53-dependent embryonic stem cell gene signature, which can serve as a potential prognostic biomarker and therapeutic target in cancer. Cancer Res; 78(20); 5833-47. ©2018 AACR.


Subject(s)
Carcinogenesis/genetics , Embryonic Stem Cells/cytology , Gene Expression Regulation, Neoplastic , Tumor Suppressor Protein p53/genetics , Animals , Biomarkers, Tumor , CRISPR-Cas Systems , Cell Line, Tumor , Cell Proliferation , Humans , Mesenchymal Stem Cells/cytology , Mice , Mice, Inbred C57BL , Mutation , Neoplasm Recurrence, Local/pathology , Neoplastic Stem Cells/pathology , Prognosis
2.
Oncogene ; 37(12): 1669-1684, 2018 03.
Article in English | MEDLINE | ID: mdl-29343849

ABSTRACT

Emerging notion in carcinogenesis ascribes tumor initiation and aggressiveness to cancer stem cells (CSCs). Specifically, colorectal cancer (CRC) development was shown to be compatible with CSCs hypothesis. Mutations in p53 are highly frequent in CRC, and are known to facilitate tumor development and aggressiveness. Yet, the link between mutant p53 and colorectal CSCs is not well-established. In the present study, we set to examine whether oncogenic mutant p53 proteins may augment colorectal CSCs phenotype. By genetic manipulation of mutant p53 in several cellular systems, we demonstrated that mutant p53 enhances colorectal tumorigenesis. Moreover, mutant p53-expressing cell lines harbor larger sub-populations of cells highly expressing the known colorectal CSCs markers: CD44, Lgr5, and ALDH. This elevated expression is mediated by mutant p53 binding to CD44, Lgr5, and ALDH1A1 promoter sequences. Furthermore, ALDH1 was found to be involved in mutant p53-dependent chemotherapy resistance. Finally, analysis of ALDH1 and CD44 in human CRC biopsies indicated a positive correlation between their expression and the presence of oncogenic p53 missense mutations. These findings suggest novel insights pertaining the mechanism by which mutant p53 enhances CRC development, which involves the expansion of CSCs sub-populations within CRC tumors, and underscore the importance of targeting these sub-populations for CRC therapy.


Subject(s)
Colorectal Neoplasms/genetics , Gain of Function Mutation , Neoplastic Stem Cells/metabolism , Tumor Suppressor Protein p53/genetics , Animals , Biomarkers, Tumor/genetics , Colorectal Neoplasms/metabolism , Female , Gene Expression Regulation, Neoplastic , Humans , Mice , Mice, Nude , Mice, Transgenic , Mutant Proteins/physiology , Mutation, Missense , Tumor Cells, Cultured
3.
Int J Cancer ; 140(6): 1364-1369, 2017 03 15.
Article in English | MEDLINE | ID: mdl-28008605

ABSTRACT

p53 loss of heterozygosity (LOH) is a frequent event in tumors of somatic and Li-Fraumeni syndrome patients harboring p53 mutation. Here, we focused on resolving a possible crosstalk between the immune-system and p53 LOH. Previously, we reported that p53 heterozygous bone-marrow mesenchymal progenitor cells undergo p53 LOH in-vivo. Surprisingly, the loss of either the wild-type p53 allele or mutant p53 allele was detected with a three-to-one ratio in favor of losing the mutant allele. In this study, we examined whether the immune-system can affect the LOH directionality in bone marrow progenitors. We found that mesenchymal progenitor cells derived from immune-deficient mice exhibited the same preference of losing the mutant p53 allele as immune-competent matched cells, nevertheless, these animals showed a significantly shorter tumor-free survival, indicating the possible involvement of immune surveillance in this model. Surprisingly, spontaneous tumors of p53 heterozygous immune-deficient mice exhibited a significantly higher incidence of p53 LOH compared to that observed in tumors derived of p53 heterozygous immune-competent mice. These findings indicate that the immune-system may affect the p53 LOH prevalence in spontaneous tumors. Thus suggesting that the immune-system may recognize and clear cells that underwent p53 LOH, whereas in immune-compromised mice, those cells will form tumors with shorter latency. In individuals with a competent immune-system, p53 LOH independent pathways may induce malignant transformation which requires a longer tumor latency. Moreover, this data may imply that the current immunotherapy treatment aimed at abrogating the inhibition of cellular immune checkpoints may be beneficial for LFS patients.


Subject(s)
Genes, p53 , Immunologic Surveillance/immunology , Loss of Heterozygosity/immunology , Lymphoma/genetics , Mesenchymal Stem Cells/metabolism , Sarcoma, Experimental/genetics , Tumor Escape , Alleles , Animals , Bone Marrow/pathology , Genotype , Homeodomain Proteins/genetics , Immunocompromised Host , Immunologic Surveillance/genetics , Interleukin-2/deficiency , Interleukin-2/genetics , Loss of Heterozygosity/genetics , Lymphoma/immunology , Lymphoma/pathology , Mesenchymal Stem Cells/pathology , Mice , Mice, Inbred C57BL , Mice, Inbred NOD , Mice, Knockout , Polymorphism, Single Nucleotide , Sarcoma, Experimental/immunology , Sarcoma, Experimental/pathology , Tumor Suppressor Protein p53/deficiency , Tumor Suppressor Protein p53/genetics
4.
Article in English | MEDLINE | ID: mdl-27235476

ABSTRACT

More than half of human tumors harbor an inactivated p53 tumor-suppressor gene. It is well accepted that mutant p53 shows an oncogenic gain-of-function (GOF) activity that facilitates the transformed phenotype of cancer cells. In addition, a growing body of evidence supports the notion that cancer stem cells comprise a seminal constituent in the initiation and progression of cancer development. Here, we elaborate on the mutant p53 oncogenic GOF leading toward the acquisition of a transformed phenotype, as well as placing mutant p53 as a major component in the establishment of cancer stem cell entity. Therefore, therapy targeted toward cancer stem cells harboring mutant p53 is expected to pave the way to eradicate tumor growth and recurrence.


Subject(s)
Gain of Function Mutation , Neoplasms/genetics , Neoplastic Stem Cells/pathology , Tumor Suppressor Protein p53/genetics , Animals , Antineoplastic Agents/pharmacology , Humans , Mice , Molecular Targeted Therapy , Neoplasms/metabolism , Neoplasms/pathology , Neoplastic Stem Cells/metabolism , Phenotype
5.
Proc Natl Acad Sci U S A ; 111(19): 7006-11, 2014 May 13.
Article in English | MEDLINE | ID: mdl-24778235

ABSTRACT

p53 is a well-known tumor suppressor that is mutated in over 50% of human cancers. These mutations were shown to exhibit gain of oncogenic function compared with the deletion of the gene. Additionally, p53 has fundamental roles in differentiation and development; nevertheless, mutant p53 mice are viable and develop malignant tumors only on adulthood. We set out to reveal the mechanisms by which embryos are protected from mutant p53-induced transformation using ES cells (ESCs) that express a conformational mutant of p53. We found that, despite harboring mutant p53, the ESCs remain pluripotent and benign and have relatively normal karyotype compared with ESCs knocked out for p53. Additionally, using high-content RNA sequencing, we show that p53 is transcriptionally active in response to DNA damage in mutant ESCs and elevates p53 target genes, such as p21 and btg2. We also show that the conformation of mutant p53 protein in ESCs is stabilized to a WT conformation. Through MS-based interactome analyses, we identified a network of proteins, including the CCT complex, USP7, Aurora kinase, Nedd4, and Trim24, that bind mutant p53 and may shift its conformation to a WT form. We propose this conformational shift as a novel mechanism of maintenance of genomic integrity, despite p53 mutation. Harnessing the ability of these protein interactors to transform the oncogenic mutant p53 to the tumor suppressor WT form can be the basis for future development of p53-targeted cancer therapy.


Subject(s)
Cell Transformation, Neoplastic/genetics , Embryonic Stem Cells/cytology , Li-Fraumeni Syndrome/genetics , Tumor Suppressor Protein p53/chemistry , Tumor Suppressor Protein p53/genetics , Adenocarcinoma , Animals , Breast Neoplasms , Cell Line , Cell Line, Tumor , Cell Proliferation , Embryonic Development/genetics , Embryonic Stem Cells/physiology , Homeodomain Proteins/genetics , Humans , Li-Fraumeni Syndrome/metabolism , Loss of Heterozygosity/physiology , Mice , Mice, Knockout , Nanog Homeobox Protein , Protein Conformation , Proteomics , Tumor Suppressor Protein p53/metabolism
6.
Carcinogenesis ; 35(6): 1196-208, 2014 Jun.
Article in English | MEDLINE | ID: mdl-24658181

ABSTRACT

It is well accepted that expression of mutant p53 involves the gain of oncogenic-specific activities accentuating the malignant phenotype. Depending on the specific cancer type, mutant p53 can contribute to either the early or the late events of the multiphase process underlying the transformation of a normal cell into a cancerous one. This multifactorial system is evident in ~50% of human cancers. Mutant p53 was shown to interfere with a variety of cellular functions that lead to augmented cell survival, cellular plasticity, aberration of DNA repair machinery and other effects. All these effects culminate in the acquisition of drug resistance often seen in cancer cells. Interestingly, drug resistance has also been suggested to be associated with cancer stem cells (CSCs), which reside within growing tumors. The notion that p53 plays a regulatory role in the life of stem cells, coupled with the observations that p53 mutations may contribute to the evolvement of CSCs makes it challenging to speculate that drug resistance and cancer recurrence are mediated by CSCs expressing mutant p53.


Subject(s)
Drug Resistance, Neoplasm/genetics , Gene Expression Regulation, Neoplastic , Mutation , Neoplastic Stem Cells/drug effects , Neoplastic Stem Cells/metabolism , Tumor Suppressor Protein p53/genetics , Animals , Genomic Instability , Humans , Signal Transduction , Tumor Suppressor Protein p53/metabolism
7.
FEBS Lett ; 588(16): 2580-9, 2014 Aug 19.
Article in English | MEDLINE | ID: mdl-24560790

ABSTRACT

The role of p53 as the "guardian of the genome" in differentiated somatic cells, triggering various biological processes, is well established. Recent studies in the stem cell field have highlighted a profound role of p53 in stem cell biology as well. These studies, combined with basic data obtained 20 years ago, provide insight into how p53 governs the quantity and quality of various stem cells, ensuring a sufficient repertoire of normal stem cells to enable proper development, tissue regeneration and a cancer free life. In this review we address the role of p53 in genomically stable embryonic stem cells, a unique predisposed cancer stem cell model and adult stem cells, its role in the generation of induced pluripotent stem cells, as well as its role as the barrier to cancer stem cell formation.


Subject(s)
Neoplastic Stem Cells/pathology , Tumor Suppressor Protein p53/metabolism , Animals , Heterozygote , Humans , Tumor Suppressor Protein p53/genetics
8.
J Cell Sci ; 125(Pt 22): 5578-86, 2012 Nov 15.
Article in English | MEDLINE | ID: mdl-22899716

ABSTRACT

Uncontrolled accumulation of reactive oxygen species (ROS) causes oxidative stress and induces harmful effects. Both high ROS levels and p53 mutations are frequent in human cancer. Mutant p53 forms are known to actively promote malignant growth. However, no mechanistic details are known about the contribution of mutant p53 to excessive ROS accumulation in cancer cells. Herein, we examine the effect of p53(R273H), a commonly occurring mutated p53 form, on the expression of phase 2 ROS-detoxifying enzymes and on the ability of cells to readopt a reducing environment after exposure to oxidative stress. Our data suggest that p53(R273H) mutant interferes with the normal response of human cells to oxidative stress. We show here that, upon oxidative stress, mutant p53(R273H) attenuates the activation and function of NF-E2-related factor 2 (NRF2), a transcription factor that induces the antioxidant response. This effect of mutant p53 is manifested by decreased expression of phase 2 detoxifying enzymes NQO1 and HO-1 and high ROS levels. These findings were observed in several human cancer cell lines, highlighting the general nature of this phenomenon. The failure of p53(R273H) mutant-expressing cells to restore a reducing oxidative environment was accompanied by increased survival, a known consequence of mutant p53 expression. These activities are attributable to mutant p53(R273H) gain of function and might underlie its well-documented oncogenic nature in human cancer.


Subject(s)
Amino Acid Substitution/genetics , Colonic Neoplasms/enzymology , Colonic Neoplasms/pathology , Metabolic Detoxication, Phase II/genetics , Mutant Proteins/metabolism , Reactive Oxygen Species/metabolism , Tumor Suppressor Protein p53/genetics , Apoptosis/drug effects , Apoptosis/genetics , Cell Proliferation/drug effects , Cell Survival/drug effects , Cell Survival/genetics , Gene Knockdown Techniques , HCT116 Cells , Heme Oxygenase-1/metabolism , Humans , Maleates/pharmacology , Mutation/genetics , NAD(P)H Dehydrogenase (Quinone)/metabolism , NF-E2-Related Factor 2/metabolism , Oxidative Stress/drug effects , Oxidative Stress/genetics , RNA, Small Interfering/metabolism , Superoxides/metabolism , Tumor Suppressor Protein p53/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...